

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/688,017	10/13/2000	Peter S. Lu	20054-001110US	7473
20350	7590 07/01/2002			
		AND CREW, LLP	ЕХАМП	NER
			DECLOUX	, AMY M
	-			
Jim vi i di moi	,	ART UNIT	PAPER NUMBER	
			1644	<u></u>
			DATE MAILED: 07/01/2002	
				/

Please find below and/or attached an Office communication concerning this application or proceeding.

*	Application No.	Applicant(s)
	09/688,017	LU ET AL.
Office Action Summary	Examiner	Art Unit
	Amy M. DeCloux	1644
The MAILING DATE f this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPI THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rej - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu - Any reply received by the Office later than three months after the mailinearned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE.	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
1)⊠ Responsive to communication(s) filed on <u>04</u>	June 2002	
	his action is non-final.	
3)☐ Since this application is in condition for allow		respectation as to the morits is
closed in accordance with the practice unde	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.
4) Claim(s) 1-30 is/are pending in the application	n.	
4a) Of the above claim(s) is/are withdra	awn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-30</u> are subject to restriction and/or	election requirement.	
Application Papers		
9)☐ The specification is objected to by the Examin	er.	
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the Exa	miner.
Applicant may not request that any objection to t		· ·
11) The proposed drawing correction filed on		oved by the Examiner.
If approved, corrected drawings are required in re	• •	
12) The oath or declaration is objected to by the E	xaminer.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documer		
2. Certified copies of the priority documer	• •	
 3. Copies of the certified copies of the pricapplication from the International B * See the attached detailed Office action for a lis 	ureau (PCT Rule 17.2(a)).	-
14)⊠ Acknowledgment is made of a claim for domes	·	
a) The translation of the foreign language pr	_	,
15) Acknowledgment is made of a claim for domes		
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)
5. Patent and Trademark Office TO-326 (Rev. 04-01) Office A	Action Summary	Part of Paper No. 7

Application/Control Number: 09/688,017

Art Unit: 1644

DETAILED ACTION

Applicant's sequence amendment filed 6-4-02 is acknowledged and has been entered. Applicant's application appears to be in sequence compliance.

Applicant claims that an "Attachment for PTO-948" was attached to the Notice to Comply with Sequence Disclosures in Paper No.4, mailed 12-12-01. The examiner has no record of such attachment in the file and it is noted that the drawing contained in the instant application have not been reviewed by the draftsman yet.

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

2.

- Claims 1-4, drawn to a method of determining the apparent affinity (Kd) of binding between a PDZ domain and a ligand, classified in class 435, subclass 7.21.
- II. Claims 5-7, drawn to a method of determining the Ki of an inhibitor of binding between a PDZ domain and a ligand, classified in class 435, subclass 7.21.
 - III. Claims 8-9, drawn to a method of identifying an agent that enhances the binding of a PDZ domain to a ligand, classified in class 435, subclass 7.21.
 - IV. Claims 13-14, drawn to a method of identifying a high specificity interaction between a particular PDZ domain and a ligand, classified in class 435, subclass 7.21.
 - V. Claim 15, drawn to a method for determining the PDZ-PL inhibition profile of a compound, classified in class 435, subclass 7.21.
- VI. Claims 16-22, drawn to an array comprising a plurality of different immobilized polypeptides, each of said polypeptides comprising a PDZ domain and a non-PDZ domain, classified in class 436, subclass 518.

Claims 23-26, drawn to a method for identifying an interaction between a PDZ domain and a PL , classified in class 435, subclass 7.21.

Claims 27-30, drawn to a method for identifying a modulator of an interaction between a PDZ and a PL, classified in class 435, subclass 7.21.

The inventions are distinct, each from the other because of the following reasons:

- 3. Inventions of Groups I-V and VII -VIII are unrelated methods. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, regarding the different inventions of Groups I-V and VII –VIII, each method has a distinct endpoint combined with a distinct set of process steps.
- 4. Group VI and Group VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the

Application/Control Number: 09/688,017

Art Unit: 1644

product as claimed can be used in a materially different process of using that product (M.P.E.P. 806.05(h)). In the present case, the product as claimed, the array, can be used as a ligand in a method of screening for monoclonal antibodies to PDZ containing polypeptides, as well as in a method of modulating a biological function of a cell.

- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and because a search in the non-patent literature of any of these distinct inventions would not be co-extensive with a search of the others, an examination and search of two or more inventions in a single application would constitute a serious undue burden on the Examiner, restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy M. DeCloux whose telephone number is 703 306-5821. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703 308-3973. The fax phone numbers for the organization where this application or proceeding is assigned are 703 305-3014 for regular communications and 703 305-7401 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0196.

Amy DeCloux, PhD,

Patent Examiner, Group 1640

June 30, 2002

Any De Cloul
7-1-07